GLP-1 use linked to fewer psychiatric hospitalizations in bipolar disorder
A large Swedish study found people with bipolar disorder had fewer psychiatric hospital stays while taking GLP-1 drugs like Ozempic or Wegovy, but experts say the finding is preliminary and does not mean these drugs treat mental illness.[1]
Researchers in Sweden report that people with bipolar disorder had significantly lower rates of psychiatric hospitalization during periods when they were taking GLP-1 medications compared with periods when they were not taking these drugs.[1] The finding comes from a large nationwide study led by Professor Mark Taylor of Griffith University's School of Medicine and Dentistry, using data from nearly 15,000 people with bipolar disorder who were prescribed GLP-1 medicines over a 15-year period.[1]
According to Taylor, people with bipolar disorder who were taking semaglutide — sold under the brand names Ozempic and Wegovy — showed lower rates of psychiatric hospitalization compared with the periods when the same patients were not on a GLP-1 drug.[1] The study design compared each person against themselves across different time periods, which is a common way researchers try to account for individual differences between patients.[1]
The source material does not give the exact size of the reduction in hospitalization rates, the statistical methods used to calculate significance, or whether the effect held for other GLP-1 drugs such as tirzepatide (Mounjaro, Zepbound) or newer agents like orforglipron (Foundayo). It is also not stated in the available reporting whether the study controlled for factors like weight loss, blood sugar control, or changes in other medications that could independently affect mental health outcomes.
Why it matters for patients
Bipolar disorder carries a high risk of psychiatric hospitalization, and any signal that a widely prescribed drug class might reduce that risk would be significant news for patients and families managing the condition. But this study is observational, meaning it tracked what happened to people already prescribed GLP-1 drugs rather than randomly assigning some patients to take the drug and others not to. Observational studies can suggest a pattern, but they cannot prove that the GLP-1 medicine caused the drop in hospitalizations.
No GLP-1 medication is currently approved by regulators for treating bipolar disorder or any other psychiatric condition. Semaglutide products like Ozempic and Wegovy are approved for type 2 diabetes and chronic weight management. People with bipolar disorder who are considering or already taking a GLP-1 drug for diabetes or weight reasons may find this news reassuring, but the study does not establish that these drugs treat mood symptoms or should be prescribed for that purpose.
Patients who take these medicines alongside psychiatric drugs, including lithium or antipsychotics commonly used for bipolar disorder, may also wonder about interactions or effects on their existing treatment plan. The available reporting does not address whether the study analyzed such combinations or their effects.
What happens next
The reporting reviewed here does not specify when or where the full study results will be published in a peer-reviewed journal, nor does it list next research steps, such as randomized trials that could test cause and effect more directly. Until such trials are conducted and published, the hospitalization pattern described by Taylor's team remains an association observed in health records rather than a proven treatment effect.[1]
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.